2022
Randomized Phase III Trial of Paclitaxel and Carboplatin Versus Paclitaxel and Ifosfamide in Patients With Carcinosarcoma of the Uterus or Ovary: An NRG Oncology Trial
Powell MA, Filiaci VL, Hensley ML, Huang HQ, Moore KN, Tewari KS, Copeland LJ, Secord AA, Mutch DG, Santin A, Warshal DP, Spirtos NM, DiSilvestro PA, Ioffe OB, Miller DS. Randomized Phase III Trial of Paclitaxel and Carboplatin Versus Paclitaxel and Ifosfamide in Patients With Carcinosarcoma of the Uterus or Ovary: An NRG Oncology Trial. Journal Of Clinical Oncology 2022, 40: 968-977. PMID: 35007153, PMCID: PMC8937015, DOI: 10.1200/jco.21.02050.Peer-Reviewed Original ResearchConceptsProgression-free survivalUterine carcinosarcomaOvarian carcinosarcomaEligible patientsHazard ratioMore patientsPC armMedian progression-free survivalRandomized phase III trialNRG Oncology trialsPhase III trialsPI armsGenitourinary hemorrhageHematologic toxicityMedian OSIII trialsLonger OSStandard treatmentGreater death rateStage IIINoninferiority designOncology trialsPatientsStage IStage IV
2020
Final results from the KEYNOTE-100 trial of pembrolizumab in patients with advanced recurrent ovarian cancer.
Matulonis U, Shapira R, Santin A, Lisyanskaya A, Pignata S, Vergote I, Raspagliesi F, Sonke G, Birrer M, Sehouli J, Colombo N, González-Martín A, Oaknin A, Ottevanger P, Rudaitis V, Wu H, Keefe S, Stein K, Ledermann J. Final results from the KEYNOTE-100 trial of pembrolizumab in patients with advanced recurrent ovarian cancer. Journal Of Clinical Oncology 2020, 38: 6005-6005. DOI: 10.1200/jco.2020.38.15_suppl.6005.Peer-Reviewed Original ResearchRecurrent advanced ovarian cancerAdvanced ovarian cancerPD-L1 expressionECOG PS 0Prior chemotherapy linesCohort AChemotherapy linesMedian OSPS 0Ovarian cancerFront-line platinum-based therapyAdvanced recurrent ovarian cancerHigh PD-L1 expressionHigh-grade serous diseaseProtocol-specified final analysisTumor PD-L1 expressionTreatment-related AEsPrimary peritoneal cancerRecurrent ovarian cancerTreatment-free intervalTreatment-related deathsModest antitumor activityModest clinical activityNew safety signalsPrimary study endpoint